Philip F Low

US Patent:

7033594, Apr 25, 2006

Filed:

Mar 30, 2001

Appl. No.:

09/822379

Inventors:

Philip Stewart Low - West Lafayette IN, US
Yingjuan Lu - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 39/00
A61K 31/495
A61K 31/445
A61K 31/50
A61K 31/34

US Classification:

4241931, 4241941, 424 851, 424 852, 424 855, 424 857, 514249, 514253, 514255, 514258

Abstract:

A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

US Patent:

7632505, Dec 15, 2009

Filed:

May 2, 2002

Appl. No.:

10/138275

Inventors:

Philip S. Low - West Lafayette IN, US
Mary Jo Turk - New York NY, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 39/00
A61K 39/38
A61K 39/385

US Classification:

4241841, 4241851, 4241931

Abstract:

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formulaA-Xwhere the group Acomprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

US Patent:

7740854, Jun 22, 2010

Filed:

May 2, 2002

Appl. No.:

10/138275

Inventors:

Philip S. Low - West Lafayette IN, US
Mary Jo Turk - New York NY, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 39/00
A61K 39/38
A61K 39/385

US Classification:

4241841, 4241851, 4241931

Abstract:

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formulaA-Xwhere the group Acomprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

US Patent:

7977058, Jul 12, 2011

Filed:

Dec 23, 2004

Appl. No.:

11/022088

Inventors:

Philip Stewart Low - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.

US Patent:

8105608, Jan 31, 2012

Filed:

Nov 16, 2005

Appl. No.:

11/274973

Inventors:

Philip Stewart Low - West Lafayette IN, US
Yingjuan Lu - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 39/00
A61K 31/495
A61K 31/445
A61K 31/50
A61K 31/34

US Classification:

4241931, 4241941, 424 851, 424 852, 424 855, 424 857, 514294, 514253, 514255, 514258

Abstract:

A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

US Patent:

8161226, Apr 17, 2012

Filed:

Dec 27, 2005

Appl. No.:

11/318868

Inventors:

Ajith K. Illendula - Albuquerque NM, US
Philip F. Low - Albuquerque NM, US

Assignee:

Intel Corporation - Santa Clara CA

International Classification:

G06F 12/02

US Classification:

711103, 711E12009

Abstract:

Example methods and apparatus to share a thread to reclaim memory space in non-volatile memory file systems are disclosed. A disclosed example method includes associating a memory reclaim thread with first and second flash memory volumes to reclaim memory space in the first and second flash memory volumes and reclaiming the memory space in at least one of the first and second flash memory volumes via the memory reclaim thread.

US Patent:

8168164, May 1, 2012

Filed:

Feb 2, 2007

Appl. No.:

12/162661

Inventors:

Philip Stewart Low - Glenview IL, US
Emanuela Ionela Sega - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 39/00

US Classification:

424 852, 4241301, 4241931

Abstract:

The invention relates to a method for enhancing an endogenous immune response-mediated elimination of a population of cancer cells in a host. The method comprises the steps of administering to the host a composition comprising an immunogen conjugated to a vitamin receptor-binding ligand selected from the group consisting of a vitamin, or an analog or a derivative thereof, and administering to the host a therapeutically effective amount of radiation wherein the amount of radiation can range from about 0. 5 to about 10 Gy per dose.

US Patent:

8383354, Feb 26, 2013

Filed:

Apr 8, 2011

Appl. No.:

13/083121

Inventors:

Philip S. Low - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.